Literature DB >> 163140

The genetics of childhood cancer.

A G Knudson.   

Abstract

Retinoblastoma should not be considered as the exceptional childhood cancer that shows dominant inheritance, but rather as the typical childhood cancer that embraces a prezygotic and postzygotic subgroup. Postzygotic cases are conceived as involving mutation as a first step too, but with the mutation in somatic rather than germinal cells. In both prezygotic and postzygotic cases a second event, possibly mutational, occurs before the cancer is initiated. The embryonal cancers are all visualized as genetic disease, and their frequencies limited by gene mutability. This mutability can be increased by environmental agents. Prezygotic cases may develop other primary tumors in other tissues. They may also have affected family members, the probability of affected offspring approaching 50%. A diagnostic test to identify prezygotic cases among those with a single primary tumor and a negative family history is sorely needed.

Entities:  

Mesh:

Year:  1975        PMID: 163140     DOI: 10.1002/1097-0142(197503)35:3+<1022::aid-cncr2820350726>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping.

Authors:  Daniel A Peiffer; Jennie M Le; Frank J Steemers; Weihua Chang; Tony Jenniges; Francisco Garcia; Kirt Haden; Jiangzhen Li; Chad A Shaw; John Belmont; Sau Wai Cheung; Richard M Shen; David L Barker; Kevin L Gunderson
Journal:  Genome Res       Date:  2006-08-09       Impact factor: 9.043

2.  Wilms' tumor and adrenocortical carcinoma with hemihypertrophy and hamartomas.

Authors:  S Müller; H Gadner; B Weber; M Vogel; H Riehm
Journal:  Eur J Pediatr       Date:  1978-03-13       Impact factor: 3.183

3.  Mutations in CIC and FUBP1 contribute to human oligodendroglioma.

Authors:  Chetan Bettegowda; Nishant Agrawal; Yuchen Jiao; Mark Sausen; Laura D Wood; Ralph H Hruban; Fausto J Rodriguez; Daniel P Cahill; Roger McLendon; Gregory Riggins; Victor E Velculescu; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Bert Vogelstein; Darell Bigner; Hai Yan; Nickolas Papadopoulos; Kenneth W Kinzler
Journal:  Science       Date:  2011-08-04       Impact factor: 47.728

4.  Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors.

Authors:  B E Johnson; A Y Sakaguchi; A F Gazdar; J D Minna; D Burch; A Marshall; S L Naylor
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

Review 5.  Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.

Authors:  J F Tarlton; D L Easty
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

6.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

7.  Retinoblastoma and the genetic theory of cancer: an old paradigm trying to survive to the evidence.

Authors:  Domenico Mastrangelo; Theodora Hadjistilianou; Sonia De Francesco; Cosimo Loré
Journal:  J Cancer Epidemiol       Date:  2009-10-27

8.  Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79.

Authors:  E Y Lee; R Bookstein; L J Young; C J Lin; M G Rosenfeld; W H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Successful treatment for a metastatic supratentorial malignant rhabdoid tumor.

Authors:  E Bouffet; D Frappaz; D Dolbeau; H Sobol; A Jouvet; C Carrie; C Pondarre; M Brunat-Mentigny; T Philip; C Mottolese
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

Review 10.  Genetics of retinoblastoma.

Authors:  F Vogel
Journal:  Hum Genet       Date:  1979-11-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.